Jorge Máspero
Universidad Autónoma de la Ciudad de México(MX)Universidad de Buenos Aires(AR)Woolcock Institute of Medical Research(AU)AstraZeneca (Australia)(AU)Fundación para la Investigación, Docencia y Prevención del Cáncer(AR)Asociación por los Derechos Civiles(AR)University of Palermo(AR)Asociación Psicoanalítica de Buenos Aires(AR)Favaloro Foundation(AR)Macquarie University(AU)
Publications by Year
Research Areas
Asthma and respiratory diseases, Allergic Rhinitis and Sensitization, Respiratory and Cough-Related Research, IL-33, ST2, and ILC Pathways, Inhalation and Respiratory Drug Delivery
Most-Cited Works
- → Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma(2018)1,869 cited
- → Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials(2019)1,404 cited
- → Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials(2015)1,159 cited
- → Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma(2018)1,122 cited
- → Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial(2016)869 cited